-
SEC Charges SafeMoon Team With Orchestrating Crypto Grand Fraud
Wednesday, November 1, 2023 - 2:24pm | 765Read More...The U.S. Securities and Exchange Commission (SEC) announced charges against cryptocurrency company SafeMoon, its creator Kyle Nagy and its U.S. counterpart SafeMoon US. The executive team, which included CEO John Karony and Chief Technical Officer Thomas Smith, were accused of...
-
Why Immunovant Could Benefit From The J&J-Momenta Deal
Wednesday, August 19, 2020 - 3:44pm | 443Read More...Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move. What Happened: Shares of New York-based Immunovant, which focuses on treatment for autoimmune disorders, gap-opened Wednesday's session higher and were seen trading with notable gains. This is despite a...
-
3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity
Monday, May 4, 2020 - 2:41pm | 676Read More...Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April. With the IPO quiet period expiring, analysts are starting coverage of the stock — and adopting a bullish...
-
Ocular Therapeutix Spikes 45% On Drug News; Morgan Stanley Upgraded Co. To Overweight
Wednesday, February 17, 2016 - 2:47pm | 208Read More...Morgan Stanley upgraded Ocular Therapeutix Inc (NASDAQ: OCUL) from Equal-Weight to Overweight ahead of news for its drug OTX-TP and the discovery of a viable pathway forward. The firm maintained its $15 price target with an in-line industry view. Analysts Andrew Berens and Thomas Smith wrote,...
